FOLH1 and metastatic neoplasm: Prostate-Specific Membrane Antigen (PSMA) is the hallmark enzyme-biomarker for prostate cancer as it is expressed in the epithelium of nearly all prostate cancers, and increased expression correlates with progression to castration resistance and metastatic disease (30–32).